Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference

▤ Summary

Cumberland Pharmaceuticals shared updated Phase 2 FIGHT DMD trial results for ifetroban at the Parent Project Muscular Dystrophy annual conference. The company highlighted additional biomarker data that supports a cardioprotective effect in Duchenne muscular dystrophy patients. The drug has already shown improvement in left ventricular ejection fraction and continues to show a favorable safety profile through 36 months of treatment. Cumberland plans to complete long-term analyses and run additional supportive studies as it advances the program.

▦ Linked Companies